Sprott’s Lucid Diagnostics LUCD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-20,000
Closed -$21.4K – 277
2026
Q2
$21.4K Hold
20,000
– – ﹤0.01% 261
2026
Q1
$23K Hold
20,000
– – ﹤0.01% 238
2025
Q4
$21.8K Sell
20,000
-5,000
-20% -$5.59K ﹤0.01% 214
2025
Q3
$25.2K Buy
+25,000
New +$27.3K ﹤0.01% 207

Other funds holding LUCD

Sprott's LUCD Position: Q3 2026 in Review

Sprott sold out of Lucid Diagnostics (LUCD) in Q3 2026, closing a stake of 20,000 shares — an estimated $21.4K sold.

Sprott first reported a position in LUCD in Q3 2025 and held it in 4 quarters. The position peaked at $25.2K in Q3 2025. 82 funds tracked by Wall St. Rank hold LUCD as of Q3 2026.

  • Sprott reported no remaining Lucid Diagnostics position as of Q3 2026 after selling out during the quarter.
  • Sprott sold 20,000 Lucid Diagnostics shares in Q3 2026, an estimated $21.4K.
  • Sprott first reported a position in Lucid Diagnostics in Q3 2025 and held it in 4 quarters.
  • Sprott's Lucid Diagnostics position peaked at $25.2K in Q3 2025.
  • 82 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q3 2026.

Based on Sprott's 13F filing for Q3 2026, filed 9 Nov 2026.